The recent approval of leucovorin by the FDA has sparked significant attention and debate, especially following its promotion by public figures such as Trump and RFK Jr. Initially recognized as a treatment for cancer, leucovorin is now being considered for use in treating autism, prompting questions about its efficacy and the scientific basis for such a shift. While some advocates hail it as a beacon of hope for families affected by autism, skepticism remains regarding its unproven status as an effective treatment. The approval process has also raised concerns about the implications for drug review standards. Experts are divided on the potential of leucovorin, with ongoing discussions about further research and its possible benefits for symptoms associated with autism.